3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill

Why It Matters

The policy shift fuels a new growth engine for diversified health insurers, boosting earnings prospects and reshaping capital allocation across the sector.

Key Takeaways

• OBBA expands HSA eligibility to bronze and catastrophic ACA plans.
• UnitedHealth's OptumRx poised for higher prescription volume from HSA growth.
• Humana gains from 2.48% Medicare Advantage rate hike in 2027.
• CVS Caremark revenue rose 11% YoY as HSA enrollment climbs.
• UnitedHealth, Humana, CVS stocks up 12‑20% in 30 days, near targets.

Pulse Analysis

The One Big Beautiful Bill’s HSA expansion marks a watershed for employer‑sponsored benefits. By allowing bronze and catastrophic ACA plans to qualify for HSAs and covering telehealth before deductibles, the legislation unlocks a previously untapped segment of the workforce—particularly gig and overtime‑heavy employees. This change not only increases cash flow into tax‑advantaged accounts but also nudges workers toward employer‑managed health plans, amplifying the role of commercial insurers in everyday medical spending.

UnitedHealth, Humana and CVS Health each illustrate how diversification can translate policy shifts into earnings momentum. UnitedHealth’s Optum ecosystem—spanning PBM, data analytics and care management—captures incremental prescription fills and specialty‑drug demand as more members enroll in HSA‑compatible coverage. Humana leverages a 2.48% Medicare Advantage rate boost slated for 2027, reinforcing its core senior market while its CenterWell unit expands commercial pharmacy and home‑health services. CVS’s Caremark division reported an 11% YoY revenue rise, reflecting deeper penetration of its PBM services among the growing HSA‑eligible base, while Aetna’s improved medical benefit ratio signals tighter cost control.

For investors, the bill creates a clear tailwind that could sustain double‑digit stock appreciation throughout 2026 and beyond. The convergence of higher employer spend, expanded telehealth coverage, and larger HSA pools strengthens cash‑flow visibility for the three firms, justifying elevated price targets. However, analysts caution that any regulatory rollback or slower employer adoption could temper the upside. Overall, the policy environment positions diversified health‑care conglomerates to capture a broader share of the commercial market, making them focal points for growth‑oriented portfolios.